3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Brain Neoplasms
4
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
35
Temozolomide
33
Filgrastim
26
Etoposide
26
Carboplatin
25
Vincristine
22
Cisplatin
22
Radiotherapy
20
Magnetic Resonance Spectroscopy
18
Thiotepa
14
Irinotecan
13
Granulocyte Colony-Stimulating Factor
12
Peripheral Blood Stem Cell Transplantation
11
Lomustine
11
Specimen Handling
9
Radiation
9
Melphalan
9
etoposide phosphate
8
Topotecan
8
Methotrexate
8
X-Rays
7
Platinum
7
Phantoms, Imaging
7
sonidegib
6
Biopsy
6
1,2-diaminocyclohexaneplatinum II citrate
6
sargramostim
5
palbociclib
5
Nuclear Medicine Department, Hospital
5
HhAntag691
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
entrectinib
×
CNS
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA